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Blood transfusions have long been a common component of
the therapy of critically ill patients, yet knowing when a
particular patient will benefit from a transfusion has not
always been clear [1]. Until recently, the ‘optimal’ hemoglobin
concentration in critically ill patients was empirically set at
10 g/dl, and most patients in critical care units received
transfusions during their stay in the unit [2,3]. There was no
evidence from clinical trials to support this practice, but some
studies had demonstrated a pathologic dependence of
oxygen consumption (VO2) on oxygen delivery (DO2) in
conditions like sepsis and acute respiratory distress
syndrome [4]. These observations spawned the hope that
increasing DO2 might improve tissue oxygenation and
ultimately decrease mortality. Most of the clinical trials that
attempted to increase DO2 did so using inotropes or
vasoactive drugs, and demonstrated no benefit in clinical
outcomes [5,6]. In both the experimental and control groups
of these studies, hemoglobin was maintained at 10 g/dl (or
hematocrit >0.30), reflecting the widely accepted threshold
for transfusion at the time. In the few studies that specifically
looked at the effect of blood transfusions on oxygen delivery
and consumption, blood tended to increase oxygen delivery
but not consumption [7,8]. To complicate matters, other
investigators suggested that the measurements
demonstrating pathologic dependence of oxygen
consumption on delivery might in fact be artifactual [4] as a
result of mathematical coupling. There were also concerns
about possible immunosuppressive [9] and microcirculatory
[10] effects of blood transfusions.
Naturally, this uncertainty in the literature about the
respective benefits and harms of transfusion spilled over into
clinical practice. As recently as the mid-1990s, papers
documented strikingly heterogeneous transfusion practices
by intensivists and suggested that a high proportion of
critically ill patients were apparently being transfused without
any clearly predisposing factors [3,11]. This debate led to a
landmark investigation into transfusion requirements in critical
care [the transfusion requirements in critical care (TRICC)
trial], which we believe has brought about a change in
practice [12]. This study was a multi-center, randomized,
controlled trial in which euvolemic patients in the intensive
care unit were randomized to either a restrictive or to a liberal
transfusion policy. In the restrictive group, patients were
transfused when the hemoglobin level was less than 7.0 g/dl,
with a target hemoglobin level of 7.0 to 9.0 g/dl. In the liberal
group, transfusions were given when the hemoglobin level
was less than 10.0 g/dl, with a target range of 10.0 to
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Abstract
Blood transfusions are commonly administered to critically ill patients, but deciding when to transfuse a
particular patient is often difficult and necessitates careful consideration of both the potential benefits
and risks. This commentary briefly discusses some of the considerations both for and against blood
transfusion in the setting of critical illness and reviews a landmark clinical trial in this area. Finally, we
reflect on the changes in attitudes towards the transfusion of blood and blood products that have
taken place over the last 20 years.
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12.0 g/dl. There were a number of exclusion criteria including
patients with ongoing bleeding or chronic anemia and
patients undergoing cardiac surgery. The study enrolled over
800 patients and demonstrated no difference in 30-day
mortality rates between the two groups. In-patient mortality
was significantly lower in the restrictive transfusion group,
and subgroup analyses in patients <55 years of age or in
those with acute physiological and chronic health evaluation
(APACHE) II scores ≤20 favored the restrictive transfusion
strategy. The average number of units of blood transfused
was 54% lower in the restrictive group than in the liberal
group. The implications of this study were that the classic
transfusion threshold of 10 g/dl [13] was unnecessarily high
for many patients in the critical care unit, and that excessive
transfusion might be harmful.
Although the results of this trial cannot be generalized to
patients with acute coronary syndromes [14] or to patients
specified in the exclusion criteria, the practical effect of this
trial has been to lower the transfusion threshold to 7 g/dl for
many patients. For those patients with a hemoglobin level
above 7 g/dl, this trial has put the onus on clinicians to justify
blood transfusion.
Notwithstanding the momentous and influential nature of this
study, it is likely that this shift in attitudes towards blood
transfusion had its roots earlier and elsewhere. No clinician in
practice in the last 20 years could miss the hesitation and frank
apprehension in the public consciousness engendered by the
widely publicized infectious hazards of the transfusion of blood
products. This underlying trepidation, spanning continents and
cultures [15–17], spurred the careful examination of blood
transfusion practices that would culminate in the TRICC trial.
Even before the TRICC trial, physicians were becoming more
reluctant to transfuse blood; the critical care literature from the
mid-1990s demonstrates striking reductions in transfusion use
in patients with burns [18] or trauma [19]. Indeed, if there was
any key moment that changed clinical practice, one could
argue that it was a simple two-page report that appeared
almost 20 years ago in Morbidity and Mortality Weekly Report.
Entitled ‘Possible transfusion-associated Acquired Immune
Deficiency Syndrome (AIDS) – California’, the case report [20]
was a harbinger of the transfusion-associated AIDS epidemic.
Two decades later, even after significant improvements in the
field of transfusion medicine which have made transfusion
safer than ever, patients and their physicians will never view
transfusion of blood and blood products in quite the same way.
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